Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

venetoclax 28Rituximab 22ibrutinib 21acalabrutinib 21Cyclophosphamide 20Specimen Handling 18obinutuzumab 15Biopsy 14fludarabine 13zanubrutinib 10pirtobrutinib 10fludarabine phosphate 9Magnetic Resonance Spectroscopy 8Bendamustine Hydrochloride 8idelalisib 6Whole-Body Irradiation 6Mycophenolic Acid 6Lenalidomide 6CT-P10 6ARQ531 6Cyclosporine 5Sirolimus 4Peripheral Blood Stem Cell Transplantation 4pembrolizumab 3Vincristine 3Tacrolimus 3Prednisone 3Doxorubicin 3Disulfides 3Cyclosporins 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphocytic, Chronic, B-Cell × voruciclib × 90 days × Clear all
NCT03547115 2026-03-17

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

MEI Pharma, Inc.

Phase 1 Terminated
84 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡